European Heart Journal

(ISSN: 0195-668X, 1522-9645)

Subscribe Submit

Articles Available on Medscape

 
 

Table of Contents

From European Heart Journal

2023 -

  • On target inhibition of vascular smooth muscle cell phenotypic transition underpins TNF-OXPHOS-AP-1 as a promising avenue for anti-remodelling interventions in aortic dissection and rupture. 
  • Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. 
  • Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). 
  • Ventricular septal defect combined with double-chambered right ventricle and severe right ventricular outflow tract stenosis in a symptom-free septuagenarian. 
  • The first European Union approval of a new medicine to treat cardiovascular diseases in 2023: why is it important to collaborate with the European Medicines Agency? 
  • Retraction of: Cardiovascular risk profile of a young adult population with high risk for obstructive sleep apnea screened by Stop-Bang and Epworth sleepiness scale in a primary health care unit. 
  • Correction to: 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). 
  • Artificial intelligence in detecting left atrial appendage thrombus by transthoracic echocardiography and clinical features: the Left Atrial Thrombus on Transoesophageal Echocardiography (LATTEE) registry. 
  • Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.